Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

News SummaryMost relevantAll newsSector newsTweets

Takeda Pharmaceutical : Supports Launch of Five-Year, $1M Initiative Spearheaded by the Massachusetts Life Sciences Center to Back Women-Driven Early Stage Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 08:16pm CET

Competitive Program to Award Two Recipients Annually with Funding and Mentorship –

Takeda Pharmaceutical Company Limited (TSE:4502) today announced its support of the launch of the MassNextGen initiative, a five-year, $1M program anchored by Takeda and matched by the Massachusetts Life Sciences Center (MLSC), to support women-led or controlled early-stage biotech companies. This highly competitive program aims to provide a year-long customized package of support that includes funding and executive coaching. The announcement was made today at Takeda Boston, which included Massachusetts Governor Charles Baker.

“Despite being essential members of the life sciences industry, women continue to be underrepresented, including at the executive level in which there remains a large gender gap,” said Christophe Bianchi M.D., President, Takeda Global Oncology Business Unit, Takeda Boston Site Head. “As an organization committed to diversity and inclusion, our contributions to the MassNextGen program and collaboration with the Massachusetts Life Sciences Center will further elevate the innovations that are being created by women-led companies, which have strong potential to make a difference in the future of our industry and the lives of patients.”

“The strength of startup life sciences companies is critical to Massachusetts innovation economy and we are committed to building diversity and empowering more women entrepreneurs in this growing field,” said Governor Charlie Baker. “This initiative will help more women-led companies to thrive, leveraging additional sources of capital and support to create new jobs and bring cutting edge innovation to the marketplace.”

“We are thrilled to begin this initiative with a strong partner in Takeda, and we look forward to collaborating with more companies, organizations and leaders to tackle this important issue,” said Lt. Governor Karyn Polito. “Through STEM-training initiatives and private sector partnerships like these, our administration is committed to increasing the representation of women in the life sciences.”

Each year, beginning in January 2018, a panel of judges comprised of representatives from MLSC, Takeda and the Executive Coaching network will select two women-owned/controlled early-stage companies to receive a year-long customized package of support through the MassNextGen program. The criteria used to determine winners will include level of involvement of women in the conception, strategy and execution of the company, the proposed use of the funds and the business plan feasibility. Each customized package will include both funding and access to a network of executive coaches that will help support, advise, and mentor the recipients.

Proposals for the first year of the program are due in February. For more information about the MassNextGen program, please visit: www.masslifesciences.com/programs/massnextgen.

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.

© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
07:31a TAKEDA PHARMACEUTICAL : Recognized as a Global 100 Most Sustainable Corporation ..
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 TAKEDA PHARMACEUTICAL : European Commission Approves ADCETRIS® (brentuximab vedo..
01/19 TAKEDA PHARMACEUTICAL : Data from Takeda Pharmaceutical Company Provide New Insi..
01/19 TAKEDA PHARMACEUTICAL : Reports from Takeda Pharmaceutical Company Provide New I..
01/18 TAKEDA PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Montana (Jan. 18)
01/18 TAKEDA PHARMACEUTICAL : Arcturus Therapeutics Announces Expansion of Collaborati..
01/11 TAKEDA PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Montana (Jan. 11)
01/11 TAKEDA PHARMACEUTICAL : and Denali Therapeutics Collaborate to Develop and Comme..
01/11 TAKEDA PHARMACEUTICAL : Denali Collaborate to Develop, Commercialize Therapies f..
More news
News from SeekingAlpha
01/22 EC OK's extension of conditional marketing status for Adcetris in lymphoma
01/12 Where To Next? Tigenix Investors Have New Stem Cell Options
01/12 Takeda's Offer On Tigenix - Good Deal Or Not?
01/08 Entera Bio Aims To Raise $55 Million In U.S. IPO
01/06 DENALI THERAPEUTICS : An IPO Trap Or Something More?
Financials ( JPY)
Sales 2018 1 742 B
EBIT 2018 -
Net income 2018 165 B
Debt 2018 736 B
Yield 2018 2,77%
P/E ratio 2018 30,45
P/E ratio 2019 33,69
EV / Sales 2018 3,37x
EV / Sales 2019 3,31x
Capitalization 5 134 B
Duration : Period :
Takeda Pharmaceutical Co L Technical Analysis Chart | 4502 | JP3463000004 | 4-Traders
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 6 698  JPY
Spread / Average Target 3,2%
EPS Revisions
Christophe Weber President, CEO & Representative Director
James Kehoe Director, Chief Financial & Corporate Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Shinji Ninomiya Manager-Research & Development
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.47%397 981
NOVARTIS1.29%226 840
PFIZER1.99%220 129
ROCHE HOLDING LTD.-4.34%211 542